Niagen Bioscience
NAGE
83 hedge funds and large institutions have $76.1M invested in Niagen Bioscience in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 12 closing their positions.
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
26% more capital invested
Capital invested by funds: $60.5M → $76.1M (+$15.5M)
8% more funds holding
Funds holding: 77 → 83 (+6)
0.85% more ownership
Funds ownership: 24.83% → 25.68% (+0.85%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$876K |
| 2 |
Renaissance Technologies
New York
|
+$750K |
| 3 |
SA
Sycale Advisors
New York
|
+$696K |
| 4 |
BlackRock
New York
|
+$450K |
| 5 |
Morgan Stanley
New York
|
+$410K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$522K |
| 2 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$486K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$349K |
| 4 |
MYIA
Mount Yale Investment Advisors
Denver,
Colorado
|
-$275K |
| 5 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$179K |
NAGE Hedge Fund Activity: Q4 2020 in Review
83 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2020, worth a combined $76.1M — up 26% from $60.5M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NAGE positions and 12 closed out — a net gain of 6 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Uniplan Investment Counsel, adding an estimated $876K. The largest seller was Millennium Management, cutting an estimated $522K.
- 83 institutional investors held Niagen Bioscience (NAGE) as of Q4 2020, up from 77 in Q3 2020.
- Funds reported $76.1M of Niagen Bioscience stock for Q4 2020, up 26% quarter-over-quarter.
- 18 funds opened new Niagen Bioscience positions in Q4 2020 and 12 closed out, a net change of +6 holders.
- The largest Niagen Bioscience buyer in Q4 2020 was Uniplan Investment Counsel, an estimated $876K added.
- The largest Niagen Bioscience seller in Q4 2020 was Millennium Management, an estimated $522K sold.
Based on aggregated 13F filings for Q4 2020.